StockData
Syndax Pharmaceuticals Inc logo

Syndax Pharmaceuticals Inc (SNDX) stock

SNDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 3/30
$9.20+0.07 (+0.77%)

Close on Nov 17, 2026Market cap $821.53MP/E –Yield –

Syndax Pharmaceuticals total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Syndax Pharmaceuticals's total debt was $344.10M at Sep 30, 2026. For fiscal 2025 it was $343.91M, down 49.1% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$343.91M-49.1%
FY2024Dec 31, 2024$675.25M–
FY2023Dec 31, 2023$0–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$344.10M+0.1%
Q2 FY2026Jun 30, 2026$344.03M+0.1%
Q1 FY2026Mar 31, 2026$343.97M+0.1%
Q4 FY2025Dec 31, 2025$343.91M-49.1%
Q3 FY2025Sep 30, 2025$343.91M–
Q2 FY2025Jun 30, 2025$343.85M–
Q1 FY2025Mar 31, 2025$343.79M–
Q4 FY2024Dec 31, 2024$675.25M–
Q4 FY2023Dec 31, 2023$0–

More Syndax Pharmaceuticals figures

See a number that looks wrong?